ArticleBMC cancer2025
Pre- and postoperative predictors of extrahepatic recurrence after curative resection for hepatocellular carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical outcomes and prognostic factors after adrenalectomy for adrenal metastasis from hepatocellular carcinoma.Annals of hepato-biliary-pancreatic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe factors associated with extrahepatic recurrence (EHR) after curative resection for hepatocellular carcinoma (HCC) have rarely been investigated. This study examined the pre- and postoperative predictors of EHR after curative resection in HCC patients over a ten-year follow-up period.
methodsA retrospective review was conducted on treatment-naïve HCC patients who underwent curative resection between 2004 and 2019 at four tertiary hospitals in South Korea. The cohort of 1,069 patients was divided into a derivation cohort (n = 683) and a validation cohort (n = 386) based on participating institutions.
resultsIn the derivation cohort, the mean age was 59.8 years, and 85.7% were male. The majority of patients (98.7%) had compensated liver cirrhosis, and chronic hepatitis B was the prevalent etiology (72.9%). EHR developed in 107 patients (15.7%) and was associated with younger age, advanced tumor stages, and histological features including larger tumor size, a higher number of tumors, the presence of microvascular invasion, serosal nvasion, intrahepatic metastasis, and necrosis. According to multivariable Cox regression analyses, younger age, a higher modified Union for International Cancer Control (UICC) stage, exceeding the Milan criteria, and an albumin-bilirubin (ALBI) grade ≥ 2 were independently significant preoperative factors associated with EHR. Similarly, age, tumor number, the presence of microvascular invasion, necrosis, exceeding the Milan criteria, and an ALBI grade ≥ 2 were independently significant postoperative factors. Kaplan-Meier plots clearly differentiated EHR-free survival among the risk groups stratified by our EHR-preop and EHR-postop models. The EHR-preop and EHR-postop models, developed in the derivation cohort, were applied to the validation cohort and showed clear separation among risk groups.
conclusionOur study developed and validated predictive models (EHR-preop and EHR-postop) to identify the risk of EHR after curative HCC resection. The models could potentially enhance clinical decision-making by identifying patients at elevated EHR risk thus advancing personalized HCC care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.